343 related articles for article (PubMed ID: 33629274)
1. Mutant Ataxin-3-Containing Aggregates (MATAGGs) in Spinocerebellar Ataxia Type 3: Dynamics of the Disorder.
Raj K; Akundi RS
Mol Neurobiol; 2021 Jul; 58(7):3095-3118. PubMed ID: 33629274
[TBL] [Abstract][Full Text] [Related]
2. Autophagy in Spinocerebellar Ataxia Type 3: From Pathogenesis to Therapeutics.
Paulino R; Nóbrega C
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108570
[TBL] [Abstract][Full Text] [Related]
3. From Pathogenesis to Novel Therapeutics for Spinocerebellar Ataxia Type 3: Evading Potholes on the Way to Translation.
Da Silva JD; Teixeira-Castro A; Maciel P
Neurotherapeutics; 2019 Oct; 16(4):1009-1031. PubMed ID: 31691128
[TBL] [Abstract][Full Text] [Related]
4. Toward therapeutic targets for SCA3: Insight into the role of Machado-Joseph disease protein ataxin-3 in misfolded proteins clearance.
Li X; Liu H; Fischhaber PL; Tang TS
Prog Neurobiol; 2015 Sep; 132():34-58. PubMed ID: 26123252
[TBL] [Abstract][Full Text] [Related]
5. Targeting the VCP-binding motif of ataxin-3 improves phenotypes in Drosophila models of Spinocerebellar Ataxia Type 3.
Johnson SL; Libohova K; Blount JR; Sujkowski AL; Prifti MV; Tsou WL; Todi SV
Neurobiol Dis; 2021 Dec; 160():105516. PubMed ID: 34563642
[TBL] [Abstract][Full Text] [Related]
6. Machado-Joseph Disease: A Stress Combating Deubiquitylating Enzyme Changing Sides.
Dantuma NP; Herzog LK
Adv Exp Med Biol; 2020; 1233():237-260. PubMed ID: 32274760
[TBL] [Abstract][Full Text] [Related]
7. Karyopherin α-3 is a key protein in the pathogenesis of spinocerebellar ataxia type 3 controlling the nuclear localization of ataxin-3.
Sowa AS; Martin E; Martins IM; Schmidt J; Depping R; Weber JJ; Rother F; Hartmann E; Bader M; Riess O; Tricoire H; Schmidt T
Proc Natl Acad Sci U S A; 2018 Mar; 115(11):E2624-E2633. PubMed ID: 29476013
[TBL] [Abstract][Full Text] [Related]
8. Caffeic acid and resveratrol ameliorate cellular damage in cell and Drosophila models of spinocerebellar ataxia type 3 through upregulation of Nrf2 pathway.
Wu YL; Chang JC; Lin WY; Li CC; Hsieh M; Chen HW; Wang TS; Wu WT; Liu CS; Liu KL
Free Radic Biol Med; 2018 Feb; 115():309-317. PubMed ID: 29247688
[TBL] [Abstract][Full Text] [Related]
9. Antisense oligonucleotide-mediated exon skipping as a strategy to reduce proteolytic cleavage of ataxin-3.
Toonen LJ; Schmidt I; Luijsterburg MS; van Attikum H; van Roon-Mom WM
Sci Rep; 2016 Oct; 6():35200. PubMed ID: 27731380
[TBL] [Abstract][Full Text] [Related]
10. The stress granule protein G3BP1 alleviates spinocerebellar ataxia-associated deficits.
Koppenol R; Conceição A; Afonso IT; Afonso-Reis R; Costa RG; Tomé S; Teixeira D; da Silva JP; Côdesso JM; Brito DVC; Mendonça L; Marcelo A; Pereira de Almeida L; Matos CA; Nóbrega C
Brain; 2023 Jun; 146(6):2346-2363. PubMed ID: 36511898
[TBL] [Abstract][Full Text] [Related]
11. Ataxin-3 protein modification as a treatment strategy for spinocerebellar ataxia type 3: removal of the CAG containing exon.
Evers MM; Tran HD; Zalachoras I; Pepers BA; Meijer OC; den Dunnen JT; van Ommen GJ; Aartsma-Rus A; van Roon-Mom WM
Neurobiol Dis; 2013 Oct; 58():49-56. PubMed ID: 23659897
[TBL] [Abstract][Full Text] [Related]
12. Ataxin-3 protein and RNA toxicity in spinocerebellar ataxia type 3: current insights and emerging therapeutic strategies.
Evers MM; Toonen LJ; van Roon-Mom WM
Mol Neurobiol; 2014 Jun; 49(3):1513-31. PubMed ID: 24293103
[TBL] [Abstract][Full Text] [Related]
13. RNA Interference Therapy for Machado-Joseph Disease: Long-Term Safety Profile of Lentiviral Vectors Encoding Short Hairpin RNAs Targeting Mutant Ataxin-3.
Nóbrega C; Codêsso JM; Mendonça L; Pereira de Almeida L
Hum Gene Ther; 2019 Jul; 30(7):841-854. PubMed ID: 30760052
[TBL] [Abstract][Full Text] [Related]
14. Comparison of spinocerebellar ataxia type 3 mouse models identifies early gain-of-function, cell-autonomous transcriptional changes in oligodendrocytes.
Ramani B; Panwar B; Moore LR; Wang B; Huang R; Guan Y; Paulson HL
Hum Mol Genet; 2017 Sep; 26(17):3362-3374. PubMed ID: 28854700
[TBL] [Abstract][Full Text] [Related]
15. Cerebellar soluble mutant ataxin-3 level decreases during disease progression in Spinocerebellar Ataxia Type 3 mice.
Nguyen HP; Hübener J; Weber JJ; Grueninger S; Riess O; Weiss A
PLoS One; 2013; 8(4):e62043. PubMed ID: 23626768
[TBL] [Abstract][Full Text] [Related]
16. Identification of the calpain-generated toxic fragment of ataxin-3 protein provides new avenues for therapy of Machado-Joseph disease| Spinocerebellar ataxia type 3.
Simões AT; Carmona V; Duarte-Neves J; Cunha-Santos J; Pereira de Almeida L
Neuropathol Appl Neurobiol; 2022 Feb; 48(1):e12748. PubMed ID: 34273111
[TBL] [Abstract][Full Text] [Related]
17. Vulnerability of frontal brain neurons for the toxicity of expanded ataxin-3.
Schmidt J; Mayer AK; Bakula D; Freude J; Weber JJ; Weiss A; Riess O; Schmidt T
Hum Mol Genet; 2019 May; 28(9):1463-1473. PubMed ID: 30576445
[TBL] [Abstract][Full Text] [Related]
18. Ataxin-3, The Spinocerebellar Ataxia Type 3 Neurodegenerative Disorder Protein, Affects Mast Cell Functions.
Sowa AS; Haas E; Hübener-Schmid J; Lorentz A
Front Immunol; 2022; 13():870966. PubMed ID: 35558088
[TBL] [Abstract][Full Text] [Related]
19. Treatment with sodium butyrate induces autophagy resulting in therapeutic benefits for spinocerebellar ataxia type 3.
Watchon M; Robinson KJ; Luu L; An Y; Yuan KC; Plenderleith SK; Cheng F; Don EK; Nicholson GA; Lee A; Laird AS
FASEB J; 2024 Jan; 38(2):e23429. PubMed ID: 38258931
[TBL] [Abstract][Full Text] [Related]
20. A Novel SCA3 Knock-in Mouse Model Mimics the Human SCA3 Disease Phenotype Including Neuropathological, Behavioral, and Transcriptional Abnormalities Especially in Oligodendrocytes.
Haas E; Incebacak RD; Hentrich T; Huridou C; Schmidt T; Casadei N; Maringer Y; Bahl C; Zimmermann F; Mills JD; Aronica E; Riess O; Schulze-Hentrich JM; Hübener-Schmid J
Mol Neurobiol; 2022 Jan; 59(1):495-522. PubMed ID: 34716557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
